Healthcare · Biotechnology
Price
$2.75
Market Cap
$1.5M
Employees
5
Beta
0.01
Avg Volume
497,437
CEO
Pnina Fishman
Business Description
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Business History
Price Overview
Last updated: Jun 27, 2026 10:02am (just now)$2.75
-0.19 (-6.46%)
Day Range
$2.59 – $3.52
52-Week Range
$2.59 – $21.80
50-Day MA
$3.15
200-Day MA
$5.67
Volume
25,142,138.00
Analyst Price Targets
Low
$5.00
Consensus
$5.00
High
$5.00
(3 analysts)
Share Structure
Outstanding
853,645.00
Float
811,772.00
Free Float
95.1%
High free float
— 95.1% of shares trade freely, ~4.9% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.8M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.23
Stock Price: $2.75
EPS (Diluted): -12.03
EPS (Diluted): -12.03
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.59
Stock Price: $2.75
Total Equity: $5.59M
Shares: 823,926
Total Equity: $5.59M
Shares: 823,926
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1,110.94
Market Cap: $1.48M
Total Debt: $0.00
Cash: $5.53M
EBITDA: -$10.00M
Total Debt: $0.00
Cash: $5.53M
EBITDA: -$10.00M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$2.2M
Market Cap: $1.48M
Total Debt: $0.00
Cash: $5.53M
Total Debt: $0.00
Cash: $5.53M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
8.07
Stock Price: $2.75
Revenue: $408,212
Shares: 823,926
Revenue: $408,212
Shares: 823,926
EV/Sales (Total value vs revenue — works when P/E can't)
API-5.29
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
94.1%
Gross Profit: $384,022
Revenue: $408,212
Revenue: $408,212
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-2,456.8%
Operating Income: -$10.03M
Revenue: $408,212
Revenue: $408,212
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-2,426.7%
Net Income: -$9.91M
Revenue: $408,212
Revenue: $408,212
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-141.0%
Net Income: -$9.91M
Total Equity: $5.59M
Total Equity: $5.59M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-101.1%
Operating Income: -$10.03M
Tax Rate: 0.0%
Equity: $5.59M
Total Debt: $0.00
Cash: $5.53M
Tax Rate: 0.0%
Equity: $5.59M
Total Debt: $0.00
Cash: $5.53M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.46
Current Assets: $9.44M
Current Liabilities: $2.73M
Current Liabilities: $2.73M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $5.59M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $5.59M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.50
Revenue: $408,212
Shares: 823,926
Shares: 823,926
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$6.79
Total Equity: $5.59M
Shares: 823,926
Shares: 823,926
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-10.95
Operating CF: -$9.02M
CapEx: -$2,018
Shares: 823,926
CapEx: -$2,018
Shares: 823,926
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.75
Stock Price: $2.75
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$9.91M
Net Income: -$9.91M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CANF against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $853,000 | $810,000 | $743,000 | $674,000 | $408,212 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $24,190 |
| Gross Profit | $853,000 | $810,000 | $743,000 | $674,000 | $384,022 |
| Operating Expenses | $13.7M | $10.9M | $8.9M | $8.8M | $10.4M |
| Operating Income | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M |
| Net Income | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.9M |
| EBITDA | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M |
| EPS | $-9.00 | $-3.75 | $-1.80 | $-1.08 | $-12.03 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.4M | $3.0M | $4.3M | $4.8M | $5.5M |
| Total Current Assets | $20.1M | $9.2M | $9.9M | $9.0M | $9.4M |
| Total Assets | $20.3M | $9.3M | $10.0M | $9.1M | $9.5M |
| Current Liabilities | $2.7M | $2.5M | $2.0M | $2.1M | $2.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.9M | $4.8M | $3.7M | $3.7M | $3.9M |
| Total Equity | $14.4M | $4.5M | $6.2M | $5.4M | $5.6M |
| Retained Earnings | -$140.7M | -$150.8M | -$158.5M | -$166.4M | -$176.2M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M |
| Capital Expenditure | $-11,000 | $-9,000 | $-2,000 | $-5,000 | $-2,018 |
| Free Cash Flow | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$3.9M | -$1.4M | $1.3M | $547,000 | $702,916 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:02am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.8M $2.8M – $2.8M
|
$31.0M $31.0M – $31.0M
|
$68.5M $68.5M – $68.5M
|
$97.3M $97.3M – $97.3M
|
| EBITDA |
-$2.8M -$2.8M – -$2.8M
|
-$31.0M -$31.0M – -$31.0M
|
-$68.5M -$68.5M – -$68.5M
|
-$97.3M -$97.3M – -$97.3M
|
| Net Income |
$-214,221 $-214,221 – $-214,221
|
$74,153 $74,153 – $74,153
|
$271,896 $271,896 – $271,896
|
$411,963 $411,963 – $411,963
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:44pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -5.0% | -8.3% | -9.3% | -39.4% |
| Gross Profit Growth | -5.0% | -8.3% | -9.3% | -43.0% |
| Operating Income Growth | +21.4% | +18.8% | +0.8% | -23.4% |
| Net Income Growth | +19.2% | +25.0% | -3.2% | -25.7% |
| EBITDA Growth | +21.4% | +18.9% | +0.7% | -23.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-04 | Farbstein Motti | A-Award | 24,000.00 | $2.04 | $49,032 |
| 2026-06-04 | Fishman Pnina | A-Award | 24,000.00 | $2.04 | $49,032 |
| 2026-04-25 | Tamir Ilan | 16,000.00 | $2.25 | $36,000 | |
| 2026-03-18 | Regev Guy | 0.00 | $0.00 | $0 | |
| 2017-02-08 | Regev Guy | 16.00 | $2,826.14 | $45,218 | |
| 2020-06-15 | Regev Guy | 200.00 | $241.47 | $48,294 | |
| 2023-08-01 | Regev Guy | 2,166.00 | $25.21 | $54,605 | |
| 2024-08-07 | Regev Guy | 2,166.00 | $26.56 | $57,529 | |
| 2026-04-25 | Regev Guy | 16,000.00 | $2.18 | $34,880 | |
| 2021-06-22 | Bornstein Yoseph | 200.00 | $241.47 | $48,294 | |
| 2023-08-01 | Bornstein Yoseph | 2,166.00 | $25.21 | $54,605 | |
| 2024-08-07 | Bornstein Yoseph | 2,166.00 | $26.56 | $57,529 | |
| 2026-04-25 | Bornstein Yoseph | 16,000.00 | $2.18 | $34,880 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CANF — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CANF.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30